CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lisata Therapeutics, Inc - LSTA CFD

3.64
4.9%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026262 %
Charges from full value of position ($-4.99)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00404 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00404%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.47
Open 3.31
1-Year Change -5.7%
Day's Range 3.31 - 3.64
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 12, 2024 3.64 0.33 9.97% 3.31 3.64 3.31
Jul 11, 2024 3.47 0.06 1.76% 3.41 3.47 3.33
Jul 10, 2024 3.33 0.03 0.91% 3.30 3.38 3.29
Jul 9, 2024 3.39 0.10 3.04% 3.29 3.40 3.29
Jul 8, 2024 3.33 -0.03 -0.89% 3.36 3.36 3.32
Jul 5, 2024 3.34 -0.01 -0.30% 3.35 3.40 3.29
Jul 3, 2024 3.29 -0.09 -2.66% 3.38 3.49 3.25
Jul 2, 2024 3.45 0.11 3.29% 3.34 3.59 3.34
Jul 1, 2024 3.51 0.12 3.54% 3.39 3.66 3.39
Jun 28, 2024 3.41 0.05 1.49% 3.36 3.41 3.36
Jun 27, 2024 3.39 0.07 2.11% 3.32 3.41 3.32
Jun 26, 2024 3.40 0.16 4.94% 3.24 3.46 3.24
Jun 25, 2024 3.44 0.15 4.56% 3.29 3.50 3.28
Jun 24, 2024 3.38 -0.11 -3.15% 3.49 3.49 3.28
Jun 21, 2024 3.38 0.16 4.97% 3.22 3.47 3.19
Jun 20, 2024 3.27 0.02 0.62% 3.25 3.40 3.17
Jun 18, 2024 3.29 -0.15 -4.36% 3.44 3.49 3.25
Jun 17, 2024 3.43 0.11 3.31% 3.32 3.47 3.29
Jun 14, 2024 3.50 0.06 1.74% 3.44 3.60 3.39
Jun 13, 2024 3.43 0.14 4.26% 3.29 3.44 3.29

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lisata Therapeutics, Inc Company profile

About Caladrius Biosciences Inc

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

Financial summary

BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).

Equity composition

Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.

Industry: Biotechnology & Medical Research (NEC)

110 Allen Road
Second Floor
07920

People also watch

Gold

2,411.42 Price
-0.180% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.60

BTC/USD

59,577.45 Price
+3.420% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

20,336.40 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,185.83 Price
+2.420% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading